Owkin Announces Partnership with Consensus to Strengthen Literature Intelligence for Owkin’s AI Scientist, K Pro
- Users of K Pro, Owkin’s AI Scientist for biology, will be able to access broad research coverage and generate answers grounded in 200M+ peer-reviewed scientific articles
Paris, France - March 3rd, 2026 - Owkin, an AI company on a mission to build biological artificial superintelligence to cure all disease, today announced a partnership with Consensus, the leading AI-powered research search engine, to bring enhanced scientific literature intelligence into Owkin’s AI Scientist for Biology, K Pro.
Through this partnership, K Pro users will be able to generate answers grounded in full‑text scientific articles - excluding redacted articles - with additional controls to refine results based on recency, citations, and journal reputation and impact. Consensus mitigates the risk of hallucination, guaranteeing every paper cited is real and every summary based on research.
The integration is designed to support more precise scientific research workflows, complementing Owkin’s expertise in multimodal analysis and data-driven biology.
Pascal Weinberger, Owkin's Co-CEO said:
“By combining Owkin’s agentic data driven approach to biological research with Consensus’s literature intelligence, we aim to help teams move faster from scientific question to evidence-based insight.”
Eric Olson, CEO of Consensus said:
“Consensus is focused on making research more trustworthy and usable at the point of decision. We’re excited to partner with Owkin to bring high-confidence literature intelligence into workflows that matter for biology and medicine.”
Press Contact: alistair.jennings@owkin.com
About Owkin
Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.
